Silence Therapeutics (SLN) Return on Invested Capital (2024 - 2026)

Silence Therapeutics has disclosed Return on Invested Capital across 3 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Invested Capital for Q1 2026 came in at 0.0%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (up 1.0% YoY), and the FY2025 annual result was 0.0%, up 1.0% from the prior year.
• Return on Invested Capital came in at 0.0% for Q1 2026 at Silence Therapeutics, up from 0.0% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.0% in Q1 2026 to a low of 0.01% in Q3 2025.
• The 3-year median for Return on Invested Capital is 0.01% (2025), against an average of 0.01%.
• Across the five-year window, Return on Invested Capital changed 0 bps in 2025 and grew 1 bps in 2026, its largest moves.
• Silence Therapeutics' Return on Invested Capital stood at 0.0% in 2024, then surged by 34 bps to 0.0% in 2025, then jumped by 48 bps to 0.0% in 2026.
• The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.